# Supplemental data

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | NEDA-3 Violation | | Relapse | | New Lesion | |
|  | HR [95%CI] | p Value | HR [95%CI] | p Value | HR [95%CI] | p Value |
| sNfL ≥ 80th percentile | 2.12 [1.16-3.87] | **0.015** | 2.01 [0.86-4.71] | 0.106 | 1.99 [1.03-3.82] | **0.040** |
| GCIP ≤ 70.4 µm | 1.36 [0.74-2.50] | 0.324 | 2.30 [0.92-5.79] | 0.076 | 1.05 [0.53-2.11] | 0.882 |
| Age | 0.99 [0.96-1.03] | 0.739 | 0.99 [0.94-1.04] | 0.668 | 0.99 [0.95-1.03] | 0.758 |
| Sex [Male] | 1.42 [0.76-2.65] | 0.275 | 1.59 [0.66-3.83] | 0.302 | 0.92 [0.46-1.83] | 0.803 |
| T2w Lesion Volume | 1.09 [1.01-1.18] | **0.027** | 1.06 [0.96-1.17] | 0.236 | 1.12 [1.03-1.22] | **0.006** |
| DMT at baseline | 1.39 [0.73-2.64] | 0.314 | 1.59 [0.62-4.04] | 0.333 | 1.09 [0.54-2.17] | 0.815 |

**Table e-5:** Multivariable Cox regression models with T2w lesion volume as the factor for lesion load

Abbreviations: NEDA-3: no evidence of disease activity-3 criteria; sNfL: serum neurofilament light chain; GCIP: ganglion cell and inner plexiform layer; T2w: T2-weighted; DMT: disease–modifying therapy.